IONS Ionis Pharmaceuticals, Inc.
Healthcare$76.07+0.68%ClosedMarket Cap: $12.57B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
25.35
P/S
11.80
EV/EBITDA
3.16
DCF Value
$-84.92
FCF Yield
-7.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
-33.3%
Net Margin
-30.9%
ROE
-58.6%
ROA
-9.5%
ROIC
-11.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $246.1M | 98.8% | $-117.4M | $-92.5M | $— | — |
| Q4 null | $203.0M | 96.1% | $-215.0M | $-229.0M | $— | — |
| FY null | $944.0M | 98.3% | $-382.0M | $-381.0M | $— | — |
| Q3 null | $156.7M | 98.5% | $-160.2M | $-128.6M | $— | — |
| Q3 null | $156.7M | 98.5% | $-160.2M | $-128.6M | $— | — |
| Q2 null | $452.0M | 99.1% | $139.8M | $123.6M | $— | — |
| Q1 null | $131.6M | 98.9% | $-146.9M | $-146.9M | $— | — |
| Q4 null | $226.6M | 98.3% | $-110.8M | $-104.3M | $— | — |
| FY null | $705.1M | 98.4% | $-475.1M | $-453.9M | $— | — |
| Q3 null | $133.8M | 99.2% | $-148.7M | $-140.5M | $— | — |
| Q2 null | $225.3M | 98.2% | $-66.1M | $-66.3M | $— | — |
| Q1 null | $119.5M | 98.2% | $-149.5M | $-142.8M | $— | — |